News about Market

Antengene Licenses ATG-106 to K2 Therapeutics in Strategic Deal

Antengene has granted K2 Therapeutics exclusive global rights to develop and commercialise ATG-106 outside Greater China under a strategic licensing agreement that also includes an option for an undisclosed bispecific T-Cell Engager (TCE).

Market | 24/06/2026 | By News Bureau |  153

BioArctic and Lilly Sign Collaboration and Research Agreement for BrainTransporter-Based Therapy

BioArctic and Lilly have entered a research and collaboration agreement to combine a Lilly compound with BioArctic’s BrainTransporter technology. BioArctic will receive a USD 30 million upfront payment under the deal.

Market | 24/06/2026 | By News Bureau

RedHill Biopharma Closes Private Placement of up to USD 19.4 Million

RedHill Biopharma has closed a private placement worth up to USD 19.4 million, including USD 6 million upfront and up to USD 13.4 million in additional proceeds from the full exercise of warrants.

Market | 23/06/2026 | By News Bureau

AbbVie to Acquire Apogee Therapeutics

AbbVie plans to acquire Apogee Therapeutics, expanding its immunology portfolio with a diverse pipeline of innovative therapies for dermatologic, respiratory, inflammatory, and immune-mediated diseases.

Market | 23/06/2026 | By News Bureau

Sun Pharma to Acquire Innovcare Lifesciences in INR 271 Crore Strategic Deal

Sun Pharma will acquire Innovcare Lifesciences for INR 271.2 crore, strengthening its presence in pharmaceuticals, nutraceuticals, and cosmeceuticals through the acquisition of the Mumbai-based healthcare company.

Market | 22/06/2026 | By News Bureau

Oncoinvent Reaches 50 Percent Enrollment Milestone in Phase 2 Trial of Ovarian Cancer Therapy Radspherin

Oncoinvent has reached the halfway enrollment point in its Phase 2 trial of Radspherin, an experimental alpha-radiation therapy for ovarian cancer patients with peritoneal metastases, as recruitment accelerates across multiple international clinical sites.

Market | 20/06/2026 | By News Bureau |  170

Innoviva Specialty Therapeutics Signs Licensing Deal with Dr. Reddy's for XACDURO

Innoviva Specialty Therapeutics and Dr. Reddy’s have entered a distribution and licensing agreement to expand access to XACDURO for serious Acinetobacter infections across South and Central America, the Caribbean, Russia, and CIS countries.

Market | 19/06/2026 | By News Bureau |  235

Assertio Announces Completion of Merger with Zydus Lifesciences

Assertio has completed its merger with Zydus Lifesciences, becoming a wholly owned subsidiary of the company. Following the acquisition, Assertio shares have been delisted from Nasdaq, with shareholders receiving USD 23.50 per share in cash.

Market | 19/06/2026 | By News Bureau |  119

Bayer Completes Acquisition of Perfuse Therapeutics

Bayer has completed the acquisition of Perfuse Therapeutics, strengthening its ophthalmology pipeline and expanding its portfolio of innovative eye disease treatments.

Market | 19/06/2026 | By News Bureau

Lupin Launches Azilsartan Medoxomil Tablets in US

Lupin has launched Azilsartan Medoxomil Tablets in the US, a bioequivalent generic version of Edarbi, indicated for the treatment of hypertension in adults.

Market | 17/06/2026 | By News Bureau |  113